INTRODUCTION
In a previous paper (Ricigliano & Penning, 1989 ) the concept that non-steroidal substrates of hydroxysteroid dehydrogenases (HSDs) could effectively be used to develop mechanism-based inactivators of this group of enzymes was presented. Some of the inherent advantages of non-steroids include the ready availability of starting materials, the diversity of electronic and molecular properties and, frequently, the ease with which reactive groups can be introduced into the molecule. In the earlier study latent Michael acceptors based on a single aromatic ring, 1-(4'-nitrophenyl)prop-2-en-l-ol (I) and 1-(4'-nitrophenyl)prop-2-yn-l-ol (II), were oxidized by homogeneous 3a-HSD of male rat liver cytosol to yield the corresponding a,zf-unsaturated ketones, 1-(4'-nitrophenyl)prop-2-en-l-one (III) and 1-(4'-nitrophenyl)prop-2-yn-1-one (IV). The oxidation products acted as enzyme-generated inactivators, producing irreversible inactivation, and the parent alcohols gave low effective partition coefficients. In addition, the chemically prepared Michael acceptors (III) and (IV) were shown to inactivate 3ac-HSD rapidly in a stoichiometric fashion.
The present paper provides evidence that the enzyme-generated inactivators (III) and (IV) are released from the site of oxidation, and ultimately bind and alkylate the nicotinamide nucleotidebinding domain of 3a-HSD.
MATERIALS AND METHODS
Nucleotides were purchased from Pharmacia-LKB Bio- technology Products (Piscataway, NJ, U.S.A.). Unlabelled steroids were purchased from Steraloids (Wilton, NH, U.S.A.).
[4-'4C]Testosterone (57.0 mCi/mmol) was purchased from Amersham (Arlington Heights, IL, U.S.A.). Affi-gel Blue was purchased from Bio-Rad Laboratories (Richmond, CA, U.S.A.).
The inactivators 1-(4'-nitrophenyl)prop-2-en-l-one and 1-(4'-nitrophenyl)prop-2-yn-1-one were synthesized as described previously (Ricigliano & Penning, 1989) . Fresh solutions of inactivators and nucleotides were prepared daily and their concentrations determined spectrophotometrically. 17,/-Bromo['4C]acetoxy-5a-dihydrotestosterone (specific radioactivity 6.6 x 103 c.p.m./nmol) was synthesized by the method of Penning et al. (1987) from bromo[l-4C]acetic acid.
Homogeneous 3a-HSD from male Sprague-Dawley rat liver was prepared and stored by the method of Penning et al. (1984) . Portions (0.4 ml) of the enzyme (4.86 mg/ml) were kept frozen at -80°C and thawed as needed. Before use enzyme was dialysed overnight against three changes of 1 mM-EDTA/10 mmpotassium phosphate buffer, pH 7.0, to remove glycerol and 2-mercaptoethanol.
The standard spectrophotometric assay for determining 3a-HSD activity was conducted at 25°C in a 1 ml system containing 75 ,uM-androsterone and 2.3 mM-NADI in 100 mM-potassium phosphate buffer, pH 7.0, with 4 % (v/v) acetonitrile as a cosolvent. The formation of reduced nicotinamide nucleotide was monitored at 340 nm, by using a molar absorption coefficient of 6270 M-1 * cm-'.
Abbreviations used: E, 3a-HSD, 3a-hydroxysteroid:NAD(P)+ oxidoreductase (EC 1.1.1.50) or 3a-hydroxysteroid dehydrogenase; HSD, hydroxysteroid dehydrogenase; allylic alcohol, l-(4'-nitrophenyl)prop-2-en-l-ol (1); acetylenic alcohol, 1-(4'-nitrophenyl)prop-2-yn-l-ol (II); enone or vinyl ketone, 1-(4'-nitrophenyl)prop-2-en-l-one (III); acetylenic ketone, 1-(4'-nitrophenyl)prop-2-yn-l-one (IV); Br-DHT, 17fl-bromoacetoxy-5a-dihydrotestosterone; androsterone, 3a-hydroxy-Sa-androstan-17-one.
RESULTS AND DISCUSSION
Inactivation of 3ac-HSD by the ailylic alcohol (I) in the presence of various concentrations of NADI Inactivation of 3a-HSD by the allylic and acetylenic alcohols has an obligatory requirement for NAD+. Previous studies published by us indicate that in the presence of 1.2 mM-NADI the allylic alcohol can promote 50 % loss of enzyme activity in 10 s at saturation and that the acetylenic alcohol can promote 50 % loss of enzyme activity in 9.9 min at saturation (Ricigliano & Penning, 1989) . [In the earlier study Fig. 2(a) should have a time scale in minutes and Fig. 2(b) in hours, and not both in hours as originally published.] By studying the rate of enzyme inactivation in the presence of the allylic alcohol and various concentrations of NADI, it was found that 0.5-1.0 mM-NAD+ was optimal for inactivation and that higher nicotinamide nucleotide concentrations significantly retarded the inactivation event (Fig. 1) . This result was unexpected, because raising the NADI concentration should increase the rate of inactivator formation, and hence the rate of inactivation. Similar results are observed with the acetylenic alcohol.
Inactivation of 30e-HSD by allylic alcohol (I) shown). These data suggest that the enzyme-generated Michael acceptors are forced to dissociate from the enzyme before inactivation, and that these compounds inactivate the enzyme by a release-and-return mechanism. With this hypothesis in mind it became crucial to determine the ultimate site of alkylation.
Inactivation of 3ac-HSD by the enone (III) in the presence of nicotinamide nucleotide
The inactivation of 3a-HSD by the enone (III) can be retarded markedly in a concentration-dependent manner by both NADH and NADPH. A representative protection experiment conducted with enone (III) is shown in Fig. 3 (kinact.) difficult (Ricigliano & Penning, 1989 Initial-rate studies in the presence of various concentrations of the enone (III) and the acetylenic ketone (IV) Initial-rate measurements of NADH production were conducted in the presence of enone or acetylenic ketone at several NADI concentrations and at a fixed androsterone concentration (75 #M). The data, shown as primary and secondary Dixon plots (Fig. 5) , indicate both the acetylenic ketone and the enone are competitive inhibitors of NAD+ binding, yielding Kd values of 7 /tM for the enone and 4 tM for the acetylenic ketone. Alternatively, initial-rate measurements of NADH production were conducted in the presence of enone or acetylenic ketone at several androsterone concentrations and at a fixed concentration of NADI (2.3 mM). These data indicate that both of the Michael acceptors are mixed competitive/non-competitive inhibitors of androsterone binding (Fig. 6) . The curvature in these plots is presumably due to the difficulty of obtaining good initial-rate data in the presence of enzyme inactivation. Because of the curvature, it was necessary to take tangents to the curves as they approach the ordinate for the secondary-plot construction. These data imply that the enone and acetylenic ketone compete with NAD+ for the nicotinamide nucleotide-binding domain and not for the steroid-binding site.
The ability to observe competitive behaviour between NAD+ and the Michael acceptors suggests that E-NAD+ does not form a ternary complex with the Michael acceptors. This rules out protection mechanisms in which the ternary complex forms but the enzyme nucleophile and Michael acceptor fail to react. It also implies that the nucleotide protection data in Fig. 3 do not result from formation of a ternary complex, and thus result from the competition of nucleotide and alkylator for free enzyme.
Accessibility of the nicotinamide nucleotide-binding site after alkylation of the enzyme with either Michael acceptor (III) or (IV) or the steroid affinity-labelling agent 17/I-bromoacetoxy-5a-dihydrotestosterone (Br-DHT)
The preceding protection data and initial-rate studies strongly suggest that the Michael acceptors alkylate the nicotinamide nucleotide-binding site. To assess the availability of this site, titrations of the enzyme's tryptophan fluorescence by NAD(P)H were performed on native enzyme, enzyme inactivated with the enone (III) and enzyme inactivated with the steroid affinity alkylator Br-DHT (Penning et al., 1987) . Fluorescence titrations ofnative enzyme have already been described (Fig. 4 Dixon (1953) . Where it was difficult to determine the slope of the primary plots because of enzyme inactivation, linear regression of the points nearest the ordinate was used to estimate the slope. These slopes were then replotted in the secondary plots (c) and (d) as suggested by Segal (1975 (Fig. 7a) , requiring a high salt concentration, 1.5 M-KCI, for removal. Like native enzyme, enzyme inactivated with the radiolabelled steroid affinity alkylator Br- [14C]DHT also binds the dye matrix tightly, requiring 1.5 M-KCI for removal (Fig. 7b) . By contrast, enzyme inactivated by the enone or the acetylenic ketone is eluted in the void volume, indicating it has no affinity for the dye matrix (Figs. 7c and 7d) . The negative deflections observed in the chromatograms are artifacts of the high-salt buffers employed.
From the data obtained with the Br-[14C]DHT-inactivated enzyme it is clear that ligands that bind the steroid-binding site do not prevent binding to an immobilized nucleotide analogue. In direct contrast, 3a-HSD inactivated by either the enone or the acetylenic ketone no longer binds to the affinity medium. This study suggests that the Michael acceptors (III) and (IV) and nucleotide bind to the same site of the enzyme rather than to distinct sites.
Kinetic model of the inactivation of 3a-HSD by Michael acceptors (III) and (IV)
In order to construct a concise model of the interactions between 3a-HSD and the aromatic Michael acceptors (III) and (IV), fundamental information describing the kinetic mechanism had to be obtained. The kinetic mechanism has been determined in this laboratory. Initial-velocity data for the NAD+-dependent oxidation of androsterone and product-inhibition studies are consistent with an ordered mechanism in which nicotinamide nucleotide binds first and leaves last (L. J. Askonas, J. W. Ricigliano & T. M. Penning, unpublished work) . Data from equilibrium binding studies (Fig. 8) also support an ordered mechanism, since 3a-HSD binds [14C]testosterone, a known competitive inhibitor of androsterone binding, only in the presence of nicotinamide nucleotide. The mechanism may further be described as sequential rather than ping-pong, on the basis of the nature of NAD+-linked dehydrogenase mechanisms, excluding those with a prosthetic group such as a flavin (Dalziel, 1975 competitive inhibition studies). The scheme predicts that in the initial-rate studies Ar=O is competitive with NAD+ and noncompetitive/mixed competitive with steroid, as is observed experimentally.
Initially, more complicated kinetic patterns were expected because the Michael acceptors should bind to the steroid-binding site where they are produced during the enzymic oxidation of their latent precursors, as well as to the nucleotide-binding site. 
NADH
Portions (100 151) of 3a-HSD (13 /LM) were subjected to equilibrium dialysis against 0.5 ml of 1 mM-EDTA/ 10 mM-potassium phosphate buffer, pH 7.0, with 6 % (v/v) acetonitrile as a co-solvent, containing 1.4 mM-NADH and increasing concentrations of ['4Cjtestosterone (71 500 c.p.m./nmol) (0-75SuM). At 0, 5, 6, 8 and 24 h, 10 j1 samples were withdrawn from both the sample and diffusate and were analysed by scintillation counting. As shown in the inset, the samples had reached equilibrium with the diffusate by 8 h. The resulting data were plotted by the method of Scatchard (1949) .
Apparently, the affinity of the active Michael acceptors for the nucleotide-binding site is substantially higher than their affinity for the steroid-binding site in the presence of NADI, effectively simplifying the kinetics.
If the latent Michael acceptors (I) and (II) (Ar-OH) are substituted for steroidal substrate in the upper cycle of Scheme 1, then the released product will be an active Michael acceptor (Ar=O). Under these conditions Scheme 1 correctly predicts a nucleotide concentration optimum for 3a-HSD inactivation by the latent Michael acceptors. Two opposing processes are involved in the NADI concentration optimum. One process, the oxidation of the latent Michael acceptors, requires NADI; the second, alkylation of free 3a-HSD by the active Michael acceptors, is inhibited by nucleotides. Because both of these processes occur simultaneously during the inactivation of 3a-HSD by the latent Michael acceptors, and have opposing NADI concentration maxima, an optimum concentration for NADI results.
Many of our findings concerning the inactivation of 3a-HSD by the aromatic Michael acceptors are accounted for in the essential features of Scheme 1 as follows. (a) The mechanism of 3a-HSD is described as ordered and sequential. an optimum for NADI concentration. (e) Because the active alkylators are released into solution before they can recombine and inactivate enzyme, 2-mercaptoethanol provides protection of 3a-HSD from inactivation by the latent Michael acceptors in the presence of NADI. The conclusion that inactivation of 3a-HSD by the active Michael acceptor occurs by alkylation of the nucleotide-binding site is supported by nucleotide protection data, the competitive binding kinetics for the Michael acceptors versus NADI and affinity-chromatography studies of native and inactivated 3a-HSD. The observation of an optimum NADI concentration for inactivation of 3a-HSD by the latent Michael acceptors is also consistent with the alkylation site being in the nucleotide-binding domain.
It is of importance to note that the inactivation of 3a-HSD by the active Michael acceptors (III) and (IV) occurs by alkylation of free enzyme. This pathway appears to be off the principal ordered kinetic path of the enzymic reaction, unless the active Michael acceptors are considered to be nucleotide analogues. Like the aromatic Michael acceptors, Br-DHT also appears to inactivate 3a-HSD through the formation of an enzyme-steroid complex that comprises a side shunt off the principal kinetic path. The same phenomena may also be observed for other HSDs interacting with mechanism-based and/or affinity alkylators. For example, 3a,20/?-HSD from Streptomyces hydrogenans (Betz & Warren, 1968) , and rat ovarian 20a-HSD (Pongsawasdi & Anderson, 1984) are believed to catalyse steroid transformation by ordered kinetic mechanisms with nucleotide binding first, yet both enzymes are inactivated by steroid affinity alkylators in the absence ofadded nucleotide (Ganguly & Warren, 1971; Sweet et al., 1972; Arias et al., 1973; Strickler et al., 1975; Covey et al., 1986; Ricigliano & Penning, 1986) .
Two possibilities are suggested by these observations. First, complexes of enzyme and inactivator, other than those for which analogous substrate complexes have been described, may be of importance in the inactivation of HSDs with ordered mechanisms. These reversible complexes may arise either from alterations in the order of inactivator binding and release relative to the order of substrate binding and release, or through dead-end shunts. Such reversible complexes may be transient in nature, and in some instances evidence of their existence comes only from the detection of the resultant inactivated enzyme. This implies that the rate of covalent bond formation is of the same order of magnitude or exceeds the dissociation rate of the reversible enzyme-inactivator complex. Secondly, each of these enzymes may actually have a minor random component to their mechanism, although the kinetically significant route for the conversion of steroids occurs by an ordered mechanism with nucleotide binding first. Although 3a,20f-HSD has a principally ordered mechanism (Betz & Warren, 1968) , it does form a small amount of E-steroid binary complex that goes on to produce product (Betz & Taylor, 1970) . Auchus & Covey (1986) have asserted that only those dehydrogenases that form kinetically significant concentrations of the binary E-inactivator complex are susceptible to true suicide inactivation. Since dehydrogenases with ordered mechanisms bind nucleotide first and release it last, their assertion carries with it the implication that enzymes that act by an ordered mechanism are refractory to steroid-based suicide inactivators. By contrast, dehydrogenases that catalyse substrate turnover by a random mechanism may be better candidates for steroid-based suicide inactivation. Our studies and those of others suggest that knowledge a priori of a target enzyme's kinetic mechanism may not reliably predict the success of a suicide substrate or mechanism-based inactivator.
This work was supported by National Institutes of Health Grant GM33464 and a Research Career Development Award CA 01335 awarded to T. M. P.
